Lumina Specialist Hospital — Executive Summary

Lumina Specialist Hospital seeks R900 million to build a 120-bed specialist hospital in South Africa — anchored by interventional cardiology, modern theatres and an intensive-care unit — reaching R666 million revenue by Year 5 and R784 million by Year 7 at a 21% EBITDA margin, delivering a 17.2% equity IRR, a 3.0× MOIC and an R141 million NPV.

Section 1 · Business Plan

Executive Summary

Lumina Specialist Hospital is a proposed 120-bed multi-disciplinary
private specialist hospital to be developed in Mbombela, Mpumalanga — a
fast-growing provincial capital that is materially under-served by
private specialist capacity. The Project seeks to raise R900m to fund
construction, equipping and the ramp-up period, establishing a regional
centre of excellence in cardiac, renal, oncology, orthopaedic and
maternal care.

1.1 The opportunity

South Africa operates a two-tier health system in which a private
sector serving roughly one-fifth of the population commands close to
half of national health expenditure. Medical schemes covered
approximately 9.17 million beneficiaries in 2024, and total benefits
paid reached R259.3 billion, of which hospitals (36%) and specialists
(28%) are by far the largest cost categories. Yet private specialist
capacity is heavily concentrated in the three metropolitan provinces and
among three incumbent groups, leaving secondary cities such as Mbombela
structurally short of advanced specialist services. The country’s
doctor-to-population ratio of about 0.31 per 1,000 — less than a third
of the World Health Organization benchmark — and acute provincial gaps
in disciplines such as nephrology and oncology underpin a durable,
demand-led investment case.

1.2 The concept

Lumina will combine acute inpatient care, modern theatres and an
intensive-care unit with five anchor service lines: an interventional
cardiology and cardiac programme (including a catheterisation
laboratory); a 20-station renal dialysis unit with nephrology cover; an
oncology centre with radiation and chemotherapy day services;
orthopaedics and surgical specialties; and a maternal and neonatal unit.
A 24/7 emergency department, diagnostic imaging (CT, MRI, ultrasound and
radiography) and an on-site pharmacy complete an integrated,
referral-friendly platform designed around the needs of medical-scheme
members, gap-cover holders and self-funding patients in the Lowveld
catchment.

Figure 1.

Figure 1. South Africa’s structural specialist-supply gap relative to international benchmarks.

1.3 Financial highlights

The base case projects revenue growing from R240m in Year 1 to R784m
by Year 7 as occupancy ramps from 45% to 74% across a phased bed
commissioning. EBITDA turns positive from the first year of operation
and reaches an EBITDA margin of 21% by Year 7 — deliberately set below
the 22–26% band reported by the listed incumbents to reflect a
conservative, ramping greenfield. Consistent with a capital-intensive
build, the venture is loss-making at the net level for its first four
years and reaches net-profit break-even in Year 5.

Year-7 revenue (base)

R784m

Year-7 EBITDA

R165m

Project IRR

16.8%

Equity MOIC (Yr-7 exit)

3.0x

Figure 2.

Figure 2. Revenue, EBITDA and EBITDA-margin trajectory (base case, R’m).

1.4 The funding request

The Project requires total funding of R900m, comprising R720m of hard
project cost plus a R180m ramp-up and debt-service reserve to bridge the
cash-absorbing build-up to stabilisation. The proposed structure blends
R450m of senior secured debt, R150m of subordinated development-finance
(mezzanine) capital that capitalises its interest during the ramp, and
R300m of equity from the Sponsor, a strategic healthcare partner and a
B-BBEE consortium.

Source of funds	Amount	% of funding
Senior secured term loan	R450m	50%
Subordinated DFI / mezzanine (PIK)	R150m	17%
Equity (sponsor + strategic + B-BBEE partner)	R300m	33%
Total funding	R900m	100%

1.5 Investment highlights & key risks

Why this is attractive

Demand-led thesis grounded in measurable structural under-supply
of private specialist care outside the major metros, reinforced by a
rising non-communicable disease burden.
Diversified, partly annuity-style revenue: chronic renal dialysis
and oncology programmes provide recurring volumes that de-risk pure
acute occupancy.
Conservative re-derivation: even after full depreciation, full
interest and 27% tax, the base case delivers a project IRR of 16.8%
against a 13.5% hurdle.
Tangible, financeable security: a freehold facility and medical
equipment provide strong collateral for senior lenders.
Clear development-finance and transformation alignment
(healthcare access, jobs, skills and B-BBEE) that fits DFI
mandates.

Key risks the reader should weigh

Ramp & break-even sensitivity: the venture
reaches net-profit break-even only at roughly 71% occupancy, a thin
margin below the 72% base-case assumption for Year 5.
Debt-service cover: DSCR is below 1.0x during
the ramp and the early-amortisation years, relying on the funded
reserve; covenants and the reserve must be sized accordingly.
Exit dependency: equity returns are materially
dependent on a Year-7 trade sale at an assumed 8.0x EBITDA; a lower
multiple or delayed exit compresses returns.
Regulatory overhang: the National Health
Insurance Act, though not yet in force, introduces long-run uncertainty
over private-sector tariffs and the role of medical schemes.
Execution: specialist recruitment,
scheme-network accreditation and construction delivery are each on the
critical path.

Confidential — this business plan is provided to prospective investors and lenders for evaluation purposes only and may not be reproduced or distributed without the written consent of Lumina Health Holdings (Pty) Ltd.